Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Recursion Pharmaceuticals

Recursion Pharmaceuticals Raises $200M

$200M
Total Raised
2013
Founded
300-500
Employees
Salt Lake City, UT
Updated October 23, 2025
2 min read

Quick Facts

Valuation
$3.5B

Recursion Pharmaceuticals Raises $200M

AI-driven drug discovery company using high-throughput biology and machine learning to find new treatments for diseases

Key Highlights

  • Funding Amount: $200M
  • Valuation: $3.5B
  • Headquarters: Salt Lake City, UT
  • Founded: 2013
  • Employees: 300-500
  • Total Raised: $676M

About the Funding Round

Recursion Pharmaceuticals has successfully closed $200M in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • Baillie Gifford
  • ARCH Venture Partners
  • Mubadala

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Recursion Pharmaceuticals achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Recursion Pharmaceuticals's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2013 and headquartered in Salt Lake City, UT, Recursion Pharmaceuticals has established itself as an innovative player in the biotech space. With 300-500 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Recursion Pharmaceuticals plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Recursion Pharmaceuticals's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Recursion Pharmaceuticals, visit their website or contact their press office.

Key Investors

Baillie Gifford
Strategic Investor
Scottish investment management firm
ARCH Venture Partners
Venture Capital
Life sciences and tech VC firm
Mubadala
Strategic Investor
Abu Dhabi sovereign wealth fund

Topics

Venture Capital(911)BiotechFunding RoundGrowth RoundUT

About the Author

David Chen
David Chen
Technology investment researcher specializing in enterprise software and infrastructure deals at top-tier venture funds.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M